NDA Submitted with Priority Review: Zeposia (ozanimod) for Ulcerative Colitis
In a news release from biopharmaceutical company Bristol Myers Squibb, the company shared that the FDA accepted its supplemental New Drug Application (sNDA). Because the sNDA was submitted alongside…